Antigen Capture and Immune Modulation by Bacterial Outer Membrane Vesicles as In Situ Vaccine for Cancer Immunotherapy Post‐Photothermal Therapy
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Tumor antigens released from tumor cells after local photothermal therapy (PTT) can activate the tumor‐specific immune responses, which are critical for eliminating the residual lesions and distant metastases. However, the limited recognition efficiency of released tumor antigens by the immune system and the immunosuppressive microenvironment lead to ineffective antitumor immunity. Here, an in situ multifunctional vaccine based on bacterial outer membrane vesicles (OMVs, 1‐MT@OMV‐Mal) is developed by surface conjunction of maleimide groups (Mal) and interior loading with inhibitor of indoleamine 2, 3‐dioxygenase (IDO), 1‐methyl‐tryptophan (1‐MT). 1‐MT@OMV‐Mal can bind to the released tumor antigens after PTT, and be efficiently recognized and taken up by dendritic cells. Furthermore, in situ injection of 1‐MT@OMV‐Mal simultaneously overcomes the immune inhibition of IDO on tumor‐infiltrating effector T cells, leading to remarkable inhibition on both primary and distant tumors. Together, a promising in situ vaccine based on OMVs to facilitate immune‐mediated tumor clearance after PTT through orchestrating antigen capture and immune modulation is presented.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Calreticulin exposure dictates the immunogenicity of cancer cell death
Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216
Mutant MHC class II epitopes drive therapeutic immune responses to cancer
Kreiter, S., Vormehr, M., van de Roemer, N., Diken, M., Löwer, M., Diekmann, J., Boegel, S., Schrörs, B., Vascotto, F., Castle, J. C., et al. (2015) · Nature · doi:10.1038/nature14426 · Cited by 1,243
Frumento, G., Rotondo, R., Tonetti, M., Damonte, G., Benatti, U., & Ferrara, G. B. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020121 · Cited by 1,133
Advances in the development of personalized neoantigen-based therapeutic cancer vaccines
Blass, E., & Ott, P. A. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00460-2 · Cited by 1,042
Cheng, K., Zhao, R., Li, Y., Qi, Y., Wang, Y., Zhang, Y., Qin, H., Qin, Y., Chen, L., Li, C., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22308-8 · Cited by 480
Self-citation
Cited by
Molecular mechanisms and therapeutic significance of Tryptophan Metabolism and signaling in cancer
Yan, J., Chen, D., Ye, Z., Zhu, X., Li, X., Jiao, H., Duan, M., Zhang, C., Cheng, J., Xu, L., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02164-y · Cited by 176
“In situ administration of 1-MT@OMV-Mal has demonstrated significant inhibition of both primary and distant CRC tumors [203].”
BackgroundStrategies for Small Extracellular Vesicle-Based Cancer Immunotherapy
Chen, Y., Tang, S., Cai, F., & Wan, Y. (2024) · Research · doi:10.34133/research.0421 · Cited by 26
Bi, Y., Chen, J., Li, Q., Li, Y., Zhang, L., Zhida, L., Yuan, F., & Zhang, R. (2024) · iScience · doi:10.1016/j.isci.2024.108833 · Cited by 24
Self-citationChen, S.-F., Ng, P.-L., Lai, C.-W., Wang, F.-J., Wang, Y.-C., Chen, M.-H., Tung, F.-I., & Liu, T.-Y. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03187-3 · Cited by 11
Metadata
- Authors
- Li, Y., Zhang, K., Wu, Y., Yue, Y., Cheng, K., Feng, Q., Ma, X., Liang, J., Ma, N., Liu, G., Nie, G., Ren, L., & Zhao, X.
- Venue
- Small
- Publisher
- Wiley
- Published
- 2022-02-12
- Volume
- 18
- Issue
- 14
- Pages
- e2107461-e2107461
- ISSN
- 1613-6810 (ISSN-L)
- 1613-6829
- OpenAlex
- W4212873521
- Cited by
- 147
- References
- 5
- FWCI
- 10.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.